ACTRN12610000168055已完成2 期
A double-blind, randomised, placebo-controlled study of the efficacy of an orally-dosed herbal formulation for the treatment of benign prostatic hypertrophy (BPH) symptoms.
Totally Natural Products0 个研究点目标入组 68 人开始时间: 2010年2月19日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 68
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 40 Years 至 80 Years（—）
- 性别
- Male
入选标准
- •1. Male aged between 40-80 years
- •2. Medically diagnosed with benign prostatic hypertrophy
- •3. Minimum score of 8 on the IPSS
排除标准
- •1. Use of a drug/natural therapy for BPH or other urological symptoms within 30 days of starting the trial.
- •2. Recently starting a bladder training program.
- •3. Urogenital surgery within the last 6 months.
- •4. A bladder biopsy and/or cystoscopy and biopsy within 30 days of starting the trial.
- •5. An indwelling catheter or practice of self-catheterisation.
- •6. Diagnosis of chronic persistant local pathology (i.e. interstitual cystitis, bladder stones).
- •7. Currently taking Warfarin or other anti-coagulant therapies.
- •8. Diagnosis of hypertension and recieving prescribed antihypertenive medications.
- •9. Diagnosis with severe renal and/or hepatic insufficiency.
- •10. Diagnosed with genital anatomical deformaties, uncontrolled diabetes, history of spinal cord injury and uncontrolled psychiatric disorders.
研究者
相似试验
进行中（未招募）
不适用
A double-blind, randomised, placebo-controlled study to investigate the tolerability and the effect of three multiple-dose regimens of BIA 9-1067 on the levodopa pharmacokinetics, catechol-0-methyltransferase activity and motor response in parkinson´s disease patients treated with levodopa/dopa-decarboxylaseinhibitorParkinson’s DiseaseMedDRA version: 17.1Level: LLTClassification code 10013113Term: Disease Parkinson'sSystem Organ Class: 100000004852EUCTR2009-012897-12-ROBIAL-Portela & Ca, SA32
已完成
3 期
A double-blind, randomised, placebo-controlled study to evaluate the effect of orally-dosed LipiSperse curcumin and/or palmitoylethanolamide (PEA) on exercise recovery in healthy males.Exercise recoveryAlternative and Complementary Medicine - Herbal remediesACTRN12618000285257RDC Global Pty Ltd42
已完成
不适用
A double-blind, randomised, placebo-controlled study to evaluate the effect of an orally-dosed herbal formulation containing Testofen, on sexual function, performance, and serum testosterone levels in healthy males.Sexual performanceSexual functionAlternative and Complementary Medicine - Herbal remediesMetabolic and Endocrine - Other metabolic disordersACTRN12611000830998AZPA International60
进行中（未招募）
1 期
Clinical trial to assess the effect of SNF472 on progression of build up of calcium in coronary blood vessels in patients with kidney disease.EUCTR2016-002834-59-ESaboratoris Sanifit450
进行中（未招募）
1 期
Clinical trial to assess the effect of SNF472 on progression of build up of calcium in coronary blood vessels in patients with kidney disease.Cardiovascular calcification in blood vessels in end-stage-renal-disease (ESRD) patients on haemodialysis (HD).MedDRA version: 20.1 Level: LLT Classification code 10014646 Term: End stage renal disease (ESRD) System Organ Class: 100000004857MedDRA version: 20.0 Level: PT Classification code 10051753 Term: Vascular calcification System Organ Class: 10047065 - Vascular disordersMedDRA version: 20.0 Level: PT Classification code 10018875 Term: Haemodialysis System Organ Class: 10042613 - Surgical and medical proceduresEUCTR2016-002834-59-GBSanifit Therapeutics S.A.270